Led · Series B · Jun 2023

Carta Healthcare provides an AI-powered platform that automates clinical data abstraction and analytics, combining machine learning with deep clinical expertise to extract and structure both structured and unstructured clinical data. Its technology generates actionable insights for health systems and life sciences organizations, streamlining data abstraction processes and reducing labor costs. The company plans to expand its customer footprint—particularly in the life sciences market—and to scale product deployment and operations following its late-2024 acquisition of Realyze Intelligence from UPMC Enterprises. The Realyze Intelligence acquisition added capabilities for rapidly analyzing data and identifying patients who match clinical trials and research studies. Founded in 2017 and headquartered in San Francisco, Carta reports consistent year-over-year growth and says the new capital will support hiring, infrastructure, and expanded market demand. The company’s CFO described Carta as financially healthy and positioned to strengthen its balance sheet and capture market opportunity. Carta Healthcare delivers collection, analysis, and insights into clinical data by providing registry data abstraction, reporting, and analytics to leading health systems. The company combines state-of-the-art technology with a team of experienced clinicians to produce high-quality registry data and associated analytics. By transforming the abstraction process and implementing powerful analytic capabilities, Carta informs data-driven decisions that can improve patient outcomes, reduce data-processing costs, and enable clinicians to spend more time on patient care. The company reports markedly faster data collection, superior data quality, and considerable cost savings for healthcare providers. Carta intends to use the recent funding to scale operations and accelerate product development to make more products accessible to more health systems. The business is focused on enhancing healthcare data processes and analytics to support better patient outcomes and research capabilities. Carta Healthcare provides AI-driven clinical data abstraction technology and services that use natural language processing and machine learning to reduce manual labor in curating trustworthy, actionable datasets. Its platform collects, analyzes, and layers analytic capabilities on clinical data to fuel data-driven healthcare decisions and improve patient care. The company supports the healthcare data registry market by transforming previously manual abstraction processes into automated workflows. Carta plans to use new funding to expand its clinical and technical teams and build new partnerships to make healthcare data more actionable. The company emphasizes making data-driven improvements to care delivery and bringing its solutions to new partners. Carta was founded in 2017 and is headquartered in San Francisco; it announced a recent Series A to accelerate growth.

Participated · Series A · May 2023

HealthSnap offers an enterprise-grade, EMR-integrated virtual care management platform that combines RPM, CCM, PCM, APCM, AI-augmented clinical workflows, enterprise analytics, reimbursement optimization, and care coordination. The company has embedded AI across care delivery to produce clinician-facing recommendations within clinician-defined protocols and safety guardrails, and launched an AI-augmented APCM solution earlier in the year. HealthSnap supports more than 80,000 active patient programs across 200 health systems and physician organizations, and projects more than 100,000 active patient programs by the end of 2026. Its platform ingests roughly two patient measurements every second, and patients see a 97% reduction in alert frequency by their twelfth month. The company reported significant commercial momentum and financial improvement, including more than fivefold revenue growth over three years, 40% year-over-year revenue growth, and a 47% year-over-year improvement in EBITDA. HealthSnap’s clinical research has shown measurable outcomes, including an average 7.3 mmHg reduction in systolic blood pressure across a cohort of more than 6,500 patients (rising to 16.7 mmHg for Stage 2 hypertensive patients) and retrospective findings of material reductions in total cost of care, hospitalizations, and ED visits among high-acuity Medicare beneficiaries.

Participated · Series A · Jul 2022

Health Note builds a pre-clinical visit automated intake platform that captures digital patient intake and prepares clinical notes for providers ahead of patient visits. The core product automates intake workflows so clinicians receive prepared clinical notes ahead of appointments. The company will use recently raised capital to accelerate market expansion and broaden its EHR integrations. Health Note also plans to invest in further R&D to build additional offerings for clinical support. The article reports no operating metrics such as revenue or user counts.

Participated · Series A · Jun 2019

RxRevu is a Denver, CO–based prescription decision-support company led by CEO Carm Huntress. Its core product, SwiftRx, brings patient-specific data from pharmacy benefit managers (PBMs) into electronic health records (EHRs), displaying accurate, real-time coverage and benefit details. The platform helps providers prescribe lower-cost medication options and reduces prior authorization volumes and downstream administrative work. The company said the new funding will be used to develop the SwiftRx platform and to expand personnel and technical capabilities. RxRevu closed a $7M Series B that brought total investment in the company to $28M. The financing was led by JAZZ Venture Partners with additional investments from existing strategic health system partners. RxRevu provides a platform and a suite of Prescription Decision Support tools that help healthcare professionals make more informed prescribing decisions. Its tools consider a patient’s medical history, individual insurance coverage and the out-of-pocket cost patients will pay at their preferred pharmacy. The platform also enables health systems to holistically manage and measure clinicians’ prescribing performance. The company is led by co-founder and CEO Carm Huntress and is based in Denver, Colorado. RxRevu raised $15.9M in a Series A round and intends to use the funds for continued growth. In conjunction with the funding, Toby Cosgrove, M.D. and Richard Zane, M.D. joined the RxRevu board of directors. RxREVU provides medication cost and quality prescription optimization solutions that help patients and payers identify cost-saving opportunities on prescription drugs. The company offers its solutions through web and mobile consumer applications. Its healthcare customers include health plans, employer groups and population health organizations. RxREVU is led by CEO Carm Huntress and Chief Medical Officer Kevin O’Brien, M.D. The company is a member of the StartUp Health Academy and has announced partnerships with Yingo Yango, Medullan and Medical Home Exchange. Those partnerships deliver patient-engagement solutions to millions of combined users.